ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) recently disclosed their fourth-quarter financial results, showing a loss of 49 cents per share, which aligns with market expectations. Research and development expenses rose to $24.5 million for the period ending on December 31, 2023. The company’s CEO emphasized advancements in their clinical initiatives and efforts to enhance their financial position.
In response to the quarterly report, analysts have adjusted their price targets for ORIC Pharmaceuticals:
– Baird lowered their price target from $27 to $25 while upholding an Outperform rating.
– Oppenheimer increased their price target from $14 to $17 and also maintained an Outperform rating.
– Wedbush analyst David Nierengarten reiterated ORIC without specifying any changes to the price target.
These revisions indicate differing views on ORIC Pharmaceuticals’ performance and future prospects, taking into account the recent financial results and strategic roadmap provided by the company’s management team.
ORIC Pharmaceuticals Stock Performance Dips Slightly on March 12, 2024: Factors to Consider for Investors
On March 12, 2024, ORIC Pharmaceuticals (ORIC) experienced a slight dip in its stock performance. Throughout the trading day, ORIC shares decreased by $0.44, resulting in a 2.94% drop in its price.
Despite this decrease, ORIC is still trading near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been performing well over a longer period of time, even with the recent drop in price.
Investors should consider various factors such as company news, industry trends, and market conditions when evaluating stock performance.
Overall, ORIC’s performance on March 12th may have been influenced by a variety of factors. Investors should continue to monitor the stock and conduct thorough research before making any investment decisions.
ORIC Pharmaceuticals (ORIC) Financial Data Analysis: Revenue Unavailable, Net Income Decline, EPS Improvement – March 12, 2024
On March 12, 2024, investors were closely watching the stock performance of ORIC Pharmaceuticals (ORIC) as the company’s financial data was under scrutiny. According to CNN Money, ORIC’s total revenue was currently unavailable, making it difficult for investors to gauge the company’s overall financial health.
The net income figures provided by CNN Money painted a somewhat bleak picture for ORIC. The company reported a net income of -$89.12 million over the past year, with a further decrease to -$25.48 million in the most recent quarter. This represented a 13.22% decrease in net income since the previous year and an 11.04% decrease since the last quarter.
Despite the decline in net income, there was a slight silver lining in the earnings per share (EPS) data. ORIC reported an EPS of -$2.25 over the past year, which was an 8.37% decrease compared to the previous year. However, the EPS increased by 11.7% since the last quarter, reaching -$0.44.
Overall, ORIC’s stock performance on March 12, 2024, was likely impacted by the mixed financial results. While the decrease in net income raised concerns among investors, the improvement in EPS could have provided some relief. Investors will continue to monitor ORIC’s financial performance closely to assess the company’s long-term prospects in the pharmaceutical industry.
